Pregnancy Exposure Registry for Vumerity (Diroximel Fumarate)

Sponsor

Biogen (Industry)

Overall Status

Not yet recruiting

CT.gov ID

NCT05658497

Collaborator

(none)

454

Enrollment

113.5

Anticipated Duration (Months)

Study Details

Study Description

Brief Summary

The primary objectives of the study are to estimate the risk of major congenital malformations (MCMs) in infants born to women with multiple sclerosis (MS) who were exposed to diroximel fumarate (DRF) at any time from 2 weeks after the first day of their last menstrual period (LMP) up through the first trimester of pregnancy and to comparatively evaluate pregnancy outcomes with MCMs in women with MS who were exposed to DRF at any time from 2 weeks after the first day of their LMP through the first trimester of pregnancy with the following: i) women with MS who were unexposed to disease modifying therapies (DMTs) and,

women with MS who were exposed to other DMTs (e.g., Avonex and Tysabri Pregnancy Registries).

The secondary objective of the study is to evaluate pregnancy outcomes in women with DRF exposure at any time from 2 weeks after the first day of their LMP through the end of pregnancy compared with the following: i) women with MS who were unexposed to DMTs, ii) women with dimethyl fumarate (DMF) exposure, iii) women with MS who were exposed to other DMTs (e.g., Avonex and Tysabri Pregnancy Registries), and iv) women without MS (e.g., women from external, general population comparators).

Condition or Disease	Intervention/Treatment	Phase
Multiple Sclerosis	Drug: Diroximel Fumarate Drug: Avonex Biological: Tysabri Drug: Dimethyl Fumarate

Study Design

Study Type:

Observational [Patient Registry]

Anticipated Enrollment :

454 participants

Observational Model:

Cohort

Time Perspective:

Prospective

Official Title:

Vumerity (Diroximel Fumarate) Prospective MS Pregnancy Exposure Registry

Anticipated Study Start Date :

Jan 20, 2023

Anticipated Primary Completion Date :

Jul 6, 2032

Anticipated Study Completion Date :

Jul 6, 2032

Arms and Interventions

Arm	Intervention/Treatment
Diroximel Fumarate Pregnant women with MS who were exposed to DRF at any time from 2 weeks after the first day of their LMP through the end of pregnancy.	Drug: Diroximel Fumarate Administered as specified in the treatment arm. Other Names: VUMERITY BIIB098
Disease Modifying Therapy (DMTs) Exposed Pregnant women with MS who were exposed to other DMTs (e.g., Avonex and Tysabri Pregnancy Registries) at any time from 2 weeks after the first day of their LMP through the end of pregnancy.	Drug: Avonex Administered as specified in the treatment arm. Other Names: BG9418 interferon beta-1a Biological: Tysabri Administered as specified in the treatment arm. Other Names: Natalizumab BG00002
DMTs Unexposed Pregnant women who were unexposed to DMT which is defined as either never received a DMT or discontinued treatment with DRF at least 1 day before 2 weeks after the first day of their LMP or discontinued a non-Registry-specified MS DMT more than 5 times its half-life prior to 2 weeks after the first day of their LMP.
Dimethyl Fumarate Pregnant women with MS who were exposed to DMF at any time from 2 weeks after the first day of their LMP through the end of pregnancy.	Drug: Dimethyl Fumarate Administered as specified in the treatment arm. Other Names: Tecfidera DMF BG00012
Women Without MS Pregnant women with external, general population comparators.

Outcome Measures

Primary Outcome Measures

Number of Major Congenital Malformations (MCMs) [Up to 52 weeks postdelivery]
MCMs include abnormalities in structural development that are medically or cosmetically significant are present at birth, and persist in postnatal life unless or until repaired as evaluated by independent advisors used throughout the registry.

Secondary Outcome Measures

Number of Elective or Therapeutic Terminations [Up to 9 months of pregnancy]
Elective or therapeutic pregnancy termination is any induced or voluntary fetal loss during pregnancy. It will be subclassified as elective or therapeutic pregnancy terminations as whether it was due to a fatal anomaly or not.
Number of Spontaneous Abortions [Before 22 weeks of gestation]
Spontaneous abortion is defined as any loss of a fetus due to natural causes before 22 weeks of gestation.
Number of Fetal Deaths Including Still Birth [At or after 22 weeks of gestation]
Fetal death or stillbirth refers to the death of a fetus prior to complete expulsion or extraction from its mother at or after 22 weeks of gestation. Death is indicated by the fact that, after such separation, the fetus does not show any evidence of life (e.g., heartbeat, umbilical cord pulsation, or definite movement of voluntary muscles). Fetal death occurring at or after 22 weeks but before 28 weeks of gestation is considered an early fetal loss. Fetal death occurring at or after 28 weeks is considered a late fetal loss.
Number of Live Births [Up to delivery (approximately 10 months)]
A live birth refers to a complete expulsion or extraction from its mother of a surviving neonate breathing, or showing any other evidence of life, such as heartbeat, umbilical cord pulsation, or definite movement of voluntary muscles, whether the umbilical cord has been cut or the placenta is attached. Any live birth before 37 weeks of gestation will be considered premature birth. Any live birth at or after 37 weeks but before 42 weeks of gestation will be considered full-term birth. Any live birth at or after 42 weeks of gestation will be considered post-term birth.
Number of Ectopic Pregnancies [Up to 9 months of pregnancy]
Number of Molar Pregnancies [Up to 9 months of pregnancy]
Number of Maternal Deaths [Up to 12 weeks postdelivery]
Maternal death is death of a pregnant woman during pregnancy, labor, or delivery. Registry will also report maternal deaths that occur up to 12 weeks postdelivery.
Number of Neonatal Deaths [Prior to 28 days postdelivery]
Neonatal death is death occurring in a neonate prior to 28 days of life.
Number of Perinatal Deaths [At or after 28 days to 12 weeks postdelivery]
Perinatal death is death occurring at or after 28 days of life and prior to 12 weeks of life.
Number of Infant Deaths [Between 12 to 52 weeks postdelivery]
Infant death is death occurring between 12 and 52 weeks of life, inclusive.
Number of Serious or Opportunistic Infections in Liveborn Children [Up to 52 weeks postdelivery]
Number of Infants with Abnormal Postnatal Growth and Development [Up to 52 weeks postdelivery]
Infant growth measurements will be used to estimate gender-specific weight-for-length, head circumference-for-age, length-for-age, and weight-for-age percentiles. Developmental milestones (i.e., social/emotional, language/communication, neurocognitive, movement/physical development) will be used to determine results of infant status (i.e., below, above, or at age-appropriate achievement).
Number of Participants with Pregnancy Complications [Up to 9 months of pregnancy]
Pregnancy complications may include incidences of preeclampsia, pregnancy-induced hypertension, preterm labor, gestational diabetes and placenta previa.

Eligibility Criteria

Criteria

Ages Eligible for Study:

N/A and Older

Sexes Eligible for Study:

Female

Accepts Healthy Volunteers:

Key Inclusion Criteria:

Participant must have a diagnosis of MS
Documentation that the participant was one of the following:

exposed to DRF at any time from 2 weeks after the first day of their LMP (i.e., conception date) up through any time during pregnancy. (If exact exposure dates are unknown, the reporter must be able to specify or estimate trimester of exposure).
unexposed to any DMT during pregnancy, defined as having never received DMT therapy; discontinued treatment with DRF at least 1 day before 2 weeks after the first day of their LMP (i.e., conception date); or discontinued a non Registry-specified MS DMT more than 5 times its half-life prior to 2 weeks after the first day of their LMP (i.e., conception date)